Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia.

ABSTRACT:

Background

This study aims to assess the cost-effectiveness and budget impact of adopting sildenafil to the benefits package for the indication of pulmonary arterial hypertension (PAH), compared to beraprost.

Methods

Based on a societal perspective, a model-based economic evaluation was performed using local and international data to quantify the potential costs and health-related outcomes in terms of life years (LYs) and quality-adjusted life years (QALYs).

Results

The economic model calculated the incremental cost-effectiveness ratio (ICER) per QALY gained for using sildenafil as first-line therapy compared to beraprost for the patient in functional class (FC) II and III, i.e. USD 3098 and USD 2827, respectively. The results indicated that in spite of sildenafil bei

SUBMITTER: Lilyasari O 

PROVIDER: S-EPMC6694473 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature